Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
MS4A6E Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 6E Similarity and Patent-Risk Signals
8 min read
MS4A6E Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 6E Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A6E sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MS4A6A Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 6A Similarity and Patent-Risk Signals
8 min read
MS4A6A Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 6A Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A6A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MS4A5 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 5 Similarity and Patent-Risk Signals
8 min read
MS4A5 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MS4A4A Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 4A Similarity and Patent-Risk Signals
8 min read
MS4A4A Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 4A Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A4A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MS4A3 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 3 Similarity and Patent-Risk Signals
8 min read
MS4A3 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MRC2 Biologics Sequence Review Report 2026: C-type mannose receptor 2 Similarity and Patent-Risk Signals
8 min read
MRC2 Biologics Sequence Review Report 2026: C-type mannose receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MRC2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP13 Biologics Sequence Review Report 2026: Collagenase 3 Similarity and Patent-Risk Signals
8 min read
MMP13 Biologics Sequence Review Report 2026: Collagenase 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP12 Biologics Sequence Review Report 2026: Macrophage metalloelastase Similarity and Patent-Risk Signals
8 min read
MMP12 Biologics Sequence Review Report 2026: Macrophage metalloelastase Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP11 Biologics Sequence Review Report 2026: Stromelysin-3 Similarity and Patent-Risk Signals
8 min read
MMP11 Biologics Sequence Review Report 2026: Stromelysin-3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP10 Biologics Sequence Review Report 2026: Stromelysin-2 Similarity and Patent-Risk Signals
8 min read
MMP10 Biologics Sequence Review Report 2026: Stromelysin-2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP7 Biologics Sequence Review Report 2026: Matrilysin Similarity and Patent-Risk Signals
8 min read
MMP7 Biologics Sequence Review Report 2026: Matrilysin Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP3 Biologics Sequence Review Report 2026: Stromelysin-1 Similarity and Patent-Risk Signals
8 min read
MMP3 Biologics Sequence Review Report 2026: Stromelysin-1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →